Pancreatic cancer
epidemiology of a bad prognosis
Abstract
Introduction: pancreatic cancer is a particularly aggressive cancer with a poor prognosis and it is typically diagnosed at a late stage. Most cases have a lower rate of resectability (10% to 20%) as a result of certain unresectable factors at the time of diagnosis.
Objective: the study aims to provide an epidemiological description of the characteristics of unresectable pancreatic cancer, palliative treatment, global survival and procedures applied. Method: descriptive, multivariable, retrospective study of cases of unresectable cancer from January 2010 to December 2015, at the 3rd Surgical Unit of Hospital Maciel, Montevideo, Uruguay.
Results: considering the 30 unresectable patients: same sex distribution. Average age was 61 years old, cephalic in 67% of cases. 53 of patients had lost weight at the time of consultation, 52% of them evidenced locoregionallymph node involvement and 50% liver metastases and/or ascites. In 52% of cases some kind of biliary bypass was performed, surgical in 53% (63% pancreaticoduodenectomy), while the rest underwent percutaneous or endoscopic surgery. 31% of patients did not receive surgical or endoscopic treatment given the advanced stage of the condition. Average survival of surgical or endoscopic treatment was 3.7 months. Conclusions: at the time of diagnosis, 50% of the cases of pancreatic cancer presented metastases and severe nutritional compromise, evidencing locoregional indicators of unresectability or incurability. One third of the cases did not receive oncological treatment given the advanced stage of the disease. Global survival was low. All of these findings suggest it is essential to devise health policies for an early diagnosis and to increase resectability rates.
References
(1) Barrios E, Musetti C, Alonso R, Garau M. V Atlas de mortalidad por cáncer en Uruguay: período 2009-2013. Montevideo: CHLCC, 2015. Disponible en: http://www.comisioncancer.org.uy/uc_428_1.html. Consulta: 14 julio 2017.
(2) Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9):1199-210.
(3) SharmaC, Eltawil KM,Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17(7):867-97.
(4) Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer 2008; 112(2):243-9.
(5) Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: diagnosis and assessment of unresectability. World J Gastroenterol 2016; 22(45):10024-37.
(6) Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol 2014; 20(31):10740-51.
(7) Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, et al. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2016; 23(12):750-5.
(8) Choi BI, Chung MJ, Han JK, Han MC, Yoon YB. Detection of pancreaticadenocarcinoma: relative value of arterial and late phases of spiral CT. Abdom Imaging 1997; 22(2):199-203.
(9) CTisus. Pancreas: tumors, CT Angiography of Pancreatic Cancer. Disponible en: http://www.ctisus.com/learning/features/syllabus%20main/pancreas-tumors-ct-angiography-of-pancreatic. Consulta: 14 julio 2017.
(10) National Cancer Institute. Surveillance, epidemiology, and End Results Programs. Cancer stat facts: pancreas cancer. Bethesda, MD: SEER, 2017. Disponible en: https://seer.cancer.gov/statfacts/html/pancreas.html. Consulta: 14 julio 2017.
(11) Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, et al. Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 2009; 16(12):3316-22.
(12) Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011; 254(2):311-9.
(13) Tachezy M, Bockhorn M, Gebauer F, Vashist YK, Kaifi JT, Izbicki JR. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? J Gastrointest Surg 2011; 15(5):829-35.
(14) Müller MW, Friess H, Köninger J, Martin D, Wente MN, Hinz U, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 2008; 195(2):221-8.
(15) Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2016; 7:CD009323.
(16) Shepherd HA, Royle G, Ross AP, Diba A, Arthur M, Colin-Jones D. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75(12):1166-8.
(17) Andersen JR, Sørensen SM, Kruse A, Rokkjaer M, Matzen P. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30(8):1132-5.
(18) Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344(8938):1655-60.
(19) Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, et al. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 2011; 40(3):415-21.
(20) Forssell H, Wester M, Akesson K, Johansson S. A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer. BMJ Open 2013; 3(12):e004064.
(21) Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM, et al. Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas 2010; 39(8):1247-53.
(22) Alonso Lárraga JO. Tratamiento de la obstrucción biliar en cáncer de páncreas. Rev Gastroenterol Méx 2012; 77(Supl 1):65-6.
(23) Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006; 63(7):986-95.
(24) Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007; 19(12):1119-24.
(25) Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery 1982; 91(2):123-33.
(26) Sarfeh IJ, Rypins EB, Jakowatz JG, Juler GL. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. Am J Surg 1988; 155(3):411-4.
(27) Jacobs PP, van der Sluis RF, Wobbes T. Role of gastroenterostomy in the palliative surgical treatment of pancreatic cancer. J Surg Oncol 1989; 42(3):145-9.
(28) Jung GS, Song HY, Kang SG, Huh JD, Park SJ, Koo JY, et al. Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. Radiology 2000; 216(3):758-63.
(29) Adler DG, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol 2002; 97(1):72-8.
(30) Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg 2011; 15(11):1917-27.
(31) Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30.
(32) Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, et al. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 2012; 215(1):41-51; discussion 51-2.
(33) Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369(18):1691-703.
(34) Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19):1817-25.
(35) Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci 2014; 105(10):1321-6.
(36) Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1):43-66.
(37) Kim HW, Lee JC, Paik KH, Lee YS, Hwang JH, Kim J. Initial metastatic site as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2015; 94(25):e1012.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
